* Bioventus Inc BVS.OQ BVS.O is expected to show a rise
in
quarterly revenue when it reports results on March 30.
* The Durham North Carolina-based company is expected to
report
a 1.8% increase in revenue to $132.699 million from $130.41
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Bioventus Inc is
for
earnings of 5 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Bioventus
Inc is
$6.5, above its last closing price of $1.41.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.12 0.12 0.08 Missed -34.4
Jun. 30 2022 0.15 0.16 0.10 Missed -35.9
Mar. 31 2022 0.05 0.05 0.04 Missed -16.7
Dec. 31 2021 0.17 0.18 0.26 Beat 46.5
Sep. 0.14 0.14 0.25 Beat 78.6
30 2021
Jun. 30 2021 0.10 0.14 0.16 Beat 16.4
Mar. 31 2021 0.10 0.10 0.15 Beat 57.9
Dec. 31 2020 0.23 0.23 2.32 Beat 908.7
This summary was machine generated March 28 at 13:02 GMT. All
figures in US dollars unless otherwise stated